Company intelligence / Profile preview

EditCo Bio

Redwood City, California, United States

Ownership: Private
Development stage: Commercial

Overview

EditCo Bio provides high-quality CRISPR-edited primary cells and optimized guide RNAs to accelerate basic biology, drug discovery, and cell/gene therapy research. Their XDel technology ensures efficient gene knockouts/knock-ins with guaranteed edits. The company does not develop its own therapeutic drugs but empowers researchers with advanced genome editing tools validated through partnerships like Promega. No clinical results as the products are intended for preclinical/research use.

Therapeutic areas: OtherOncologyNeurology
Modalities: CRISPR-based therapyGene editing tools/reagentsCell engineering services
Industry: Non-Drug Biotech

Partnerships

Promega Corporation

Beyond the preview

Go deeper on EditCo Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EditCo Bio.

Explore the full profile